Understand what a "hot issue" IPO is, why it's oversubscribed, and how it attracts both long-term investors and speculators looking for short-term gains. Explore what makes companies in high-tech ...

The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a public listing that could see proceeds of around $210m. The cancer treatment-focused biotech ...

Something big is lining up for 2026, and it’s not just another IPO cycle. Wall Street is staring at one of the most crowded public-market queues in years, with 190+ companies racing toward the exit at ...